MedTrace Logo

Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)

NCT01071707 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2012-10-17

No results posted yet for this study

Summary

Study purpose:

The disease course of idiopathic pulmonary fibrosis (IPF) is variable. During the course of the disease some patients will get better, some will stay the same, and others will get worse. Currently doctors do not have any way to predict an individual patients disease course. The purpose of this study is to determine if 'biomarkers' such as proteins or genes isolated at the time of diagnosis can be used to predict the disease course. These 'biomarkers' will be obtained from samples of blood, from a procedure call a bronchoscopy, and in some patients from extra tissue obtained by a surgical lung biopsy.

Conditions

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Michigan

    lead OTHER

Principal Investigators

  • Herbert Reynolds, MD · National Heart, Lung and Blood Institute, Division of Lung Sciences, National Institute of Health

  • Fernando J Martinez, MD,MS · University of Michigan

  • Galen B Toews, MD · University of Michigan

  • Kevin R Flaherty, MD, MS · University of Michigan

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01071707 on ClinicalTrials.gov